Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CVM vs ENTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: CVM 2 – 3 ENTX (1 Tie) Matrix Metrics: CVM 3 – 5 ENTX

As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas ENTX carries 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. CVM 43.5/100 HOLD) and 1.07β · 45% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs ENTX
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.91
+14.76% 1D
Market Cap $22.5M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.45β · 139% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 61.8 · SMA20: $1.48 · SMA50: $1.67
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap $541.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 45% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 35.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.8 · SMA20: $3.09 · SMA50: $2.90

6-Pillar Scorecard Institutional Category Breakdown (CVM 2 – 3 ENTX)

Columns: Metric · CVM · ENTX
1. Valuation Multiples CVM
Forward P/E 23.0x N/M
Trailing P/E 23.0x N/M
PEG Ratio 1.12x N/M
EV / Revenue N/M N/M
2. Growth & Scale CVM
Revenue Growth (YoY) -62.7% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28,558 N/A
Market Cap $22.5M $541.6M
3. Profitability & Quality ENTX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -252.5% -20.3%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$17M -$16M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 113.8% (32nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (3) vs ENTX (5)
Institutional Metric CVM ENTX Criterion Row Edge
Market Capitalization
Scale
$22.5M $541.6M Larger Scale ENTX
Trailing P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Revenue Growth (YoY)
Growth
-62.7% -100.0% Higher Growth CVM
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-252.5% -20.3% Higher ROE ENTX
52-Week Range Position
Momentum
15% ($1–$8) 64% ($1–$4) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
0.45β · 139% Vol 1.07β · 45% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 53.5 / 100 (HOLD) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
$28,558 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) -$16M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVM +13.07 pp
CVM: +15.45% · ENTX: +2.38%
3M Horizon CVM +19.38 pp
CVM: +16.16% · ENTX: -3.22%
6M Horizon ENTX +117.2 pp
CVM: +19.81% · ENTX: +137.01%
1Y Horizon ENTX +82.29 pp
CVM: -71.22% · ENTX: +11.07%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CVM Revenue ENTX Revenue CVM Op. Margin ENTX Op. Margin Margin Leader
FY2012 $0M N/A -6772.3% N/A CVM
FY2013 $0M N/A -12450.1% N/A CVM
FY2014 $0M N/A -9721.4% N/A CVM
FY2020 N/A $0M N/A -3059.7% ENTX
FY2021 N/A $0M N/A -2139.6% ENTX
FY2022 N/A $0M N/A -9714.2% ENTX
FY2024 N/A $0M N/A -5295.6% ENTX
FY2025 N/A $0M N/A -27450.0% ENTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
80d in phase · OBV NEUTRAL
Current IV 113.8%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs ENTX Key Questions & Quantitative Answers

As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas ENTX carries 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. CVM 43.5/100 HOLD) and 1.07β · 45% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CVM leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), CVM cumulative revenue shifted N/A while ENTX shifted N/A. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.

CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus ENTX (-20.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.45β · 139% Vol realized risk). By comparison, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.